D2C-firstUS

Niagen Bioscience benchmarks

NAGE · United States

How Niagen Bioscience runs its business, at a glance: $122M in revenue in the last 12 months (-1.9%), compared with 30 other D2C-first brands on growth, margins and marketing. 16 fiscal years since 2010 and 65 quarters from SEC filings.

Compare your brandSee peersFull history

Revenue, last 12 months$122M-1.9% on the year before · #133 of 180 by revenue
Growth-1.9%Below the D2C-first median
Gross margin63.9%Above the D2C-first median
Marketing31.8%Spends more than the D2C-first median
Operating margin+3.9%Above the D2C-first median

Operating scorecard

The numbers that show how Niagen Bioscience runs: what it keeps from each sale, what it spends to win customers, and what is left. Each card shows the trend and where Niagen Bioscience ranks.

Revenue, last 12 months

$122M-1.9% on a year earlier

In USD, as reported, 12 months to 2026-09.

2016: $22M2017: $21M2018: $32M2019: $46M2020: $59M2021: $67M2022: $72M2023: $84M2024: $100M2025: $129M
20162025

#133 by revenue of 180 brands in the benchmark.

Revenue growth

-1.9%▼ 31.9 pts vs 2025

Revenue against the year before

2016: +21.1% (peer median +8.2%)2017: -2.1% (peer median +15.5%)2018: +48.8% (peer median +14%)2019: +46.7% (peer median +16.7%)2020: +28% (peer median +38.3%)2021: +13.8% (peer median +25.7%)2022: +6.8% (peer median +1.7%)2023: +16% (peer median -0.9%)2024: +19.2% (peer median -2%)2025: +29.9% (peer median +2.3%)
2016peer median2025

Below the D2C-first median (+4.1%). Grows faster than 30% of all 174 brands.

Gross margin

63.9%▼ 0.4 pts vs 2025

Left of each sale after product and delivery costs

2016: 48% (peer median 44.4%)2017: 49.4% (peer median 43.2%)2018: 50.9% (peer median 43.9%)2019: 55.7% (peer median 47%)2020: 59.5% (peer median 46.5%)2021: 61.5% (peer median 49.2%)2022: 59.4% (peer median 47.1%)2023: 60.8% (peer median 49.7%)2024: 61.8% (peer median 50.4%)2025: 64.3% (peer median 54.3%)
2016peer median2025

Above the D2C-first median (54.6%). Higher margin than 80% of all 169 brands.

Marketing spend

31.8%▲ 4.4 pts vs 2025

Share of revenue spent on marketing and advertising

2016: 7.2% (peer median 15.4%)2017: 21% (peer median 9.8%)2018: 52.4% (peer median 16.8%)2019: 39.4% (peer median 19.6%)2020: 35.4% (peer median 20.7%)2021: 42% (peer median 16.4%)2022: 39.3% (peer median 21.4%)2023: 31.6% (peer median 19.6%)2024: 29.6% (peer median 19.2%)2025: 27.4% (peer median 16.3%)
2016peer median2025

Spends more than the D2C-first median (16.4%). Spends more than 87% of all 144 brands.

Headroom

32%▼ 4.8 pts vs 2025

Gross margin minus marketing: what is left for the team, rent and profit

2016: 40.8% (peer median 31.3%)2017: 28.4% (peer median 29.2%)2018: -1.5% (peer median 26.7%)2019: 16.3% (peer median 30.6%)2020: 24.2% (peer median 31.2%)2021: 19.5% (peer median 26.8%)2022: 20.1% (peer median 20.6%)2023: 29.1% (peer median 26.7%)2024: 32.2% (peer median 27.5%)2025: 36.8% (peer median 31.3%)
2016peer median2025

Above the D2C-first median (31%). More headroom than 44% of all 137 brands.

Operating margin

+3.9%▼ 8.7 pts vs 2025

Profit from operations, before interest and tax

2016: -13.4% (peer median +0.9%)2017: -77.2% (peer median -4.4%)2018: -105.1% (peer median -4.7%)2019: -67.6% (peer median -4.2%)2020: -33.5% (peer median +4.2%)2021: -40.1% (peer median +4.5%)2022: -25.9% (peer median -0.1%)2023: -6.7% (peer median -4.2%)2024: +7.8% (peer median +0.7%)2025: +12.6% (peer median +0.8%)
2016peer median2025

Above the D2C-first median (+1.7%). More profitable than 57% of all 178 brands.

Niagen Bioscience: 12 months to 2026-09. Trend lines: the last 10 fiscal years, dashed line the median D2C-first brand in the same year. Bars: where Niagen Bioscience sits among all 180 brands, from lowest to highest.

Where every 100 of revenue goes

For every 100 Niagen Bioscience takes in: what the products cost to make and deliver, what goes to marketing, what runs the company, and what is left as profit.

Product and deliveryMarketingTeam, rent and other costsOperating profitLoss (costs above revenue)

Niagen Bioscience12 months to 2026-09
Niagen BioscienceFY 2010
D2C-first median30 brands
All brands median180 brands

Medians are worked out line by line, so their parts can add up to slightly more or less than 100. Product and delivery is revenue minus gross profit; how much shipping sits there differs by company.

Compare your brand

Type in your own numbers to see where you stand against Niagen Bioscience, the median D2C-first brand, and all 180 brands.

Your last 12 months, as % of revenue. Nothing you type leaves this page.

Your numbers against Niagen Bioscience and the D2C-first median
MetricYouNiagen BioscienceGapD2C-firstmedianAmong all brands
Revenue growth–-1.9%–+4.1%–
Gross margin–63.9%–54.6%–
Marketing spend–31.8%–16.4%–
Headroom–32%–31%–
Operating margin–+3.9%–+1.7%–

Niagen Bioscience and its peers

D2C-first brands of a similar size, side by side.

All D2C-first brands
Niagen Bioscience and the closest D2C-first brands by revenue
BrandRevenueGrowthGross marginMarketingHeadroomOp. margin
Niagen BioscienceNAGE · US $122M-1.9%63.9%31.8%32%+3.9%
Nelly GroupNELLY · Europe SEK 1.26B+15.5%54.3%9.9%44.4%+13.2%
WittchenWTN · Europe PLN 477M+5%61.7%––+10%
Laird SuperfoodLSF · US $111M+129.6%30.9%19.8%11.1%-4%
SFDSFD · Europe PLN 441M+24%–––+2.1%
ProCookPROC · Europe £85M+23%67.5%––+5.7%
Byrna TechnologiesBYRN · US $96M-13.4%54.6%22.5%32.1%-11.4%
Virgin Wines UKVINO · Europe £61M+3.4%28.3%––-2.8%
D2C-first median30 brands+4.1%54.6%16.4%31%+1.7%

The 7 D2C-first brands closest to Niagen Bioscience in revenue. Green: above the median, grey: below. Revenue in each company's own currency.

Revenue by year

Every fiscal year on record, in USD. Point at a bar for growth and margins.

FY 2010: revenue $7.6M, gross margin 38.9%, marketing 14.3%, operating margin -26.7% FY 2011: revenue $8.1M, +7.2% on a year earlier, gross margin 30.5%, marketing 31.3%, operating margin -96.9% 2011FY 2012: revenue $12M, +43.1% on a year earlier, gross margin 19.6%, marketing 47.5%, operating margin -100.2% FY 2013: revenue $10M, -12.5% on a year earlier, gross margin 30.8%, marketing 23.2%, operating margin -43.2% 2013FY 2014: revenue $15M, +50.7% on a year earlier, gross margin 34.8%, marketing 14%, operating margin -34.2% FY 2015: revenue $18M, +16.8% on a year earlier, gross margin 42.1%, marketing 8.4%, operating margin -11.6% 2015FY 2016: revenue $22M, +21.1% on a year earlier, gross margin 48%, marketing 7.2%, operating margin -13.4% FY 2017: revenue $21M, -2.1% on a year earlier, gross margin 49.4%, marketing 21%, operating margin -77.2% 2017FY 2018: revenue $32M, +48.8% on a year earlier, gross margin 50.9%, marketing 52.4%, operating margin -105.1% FY 2019: revenue $46M, +46.7% on a year earlier, gross margin 55.7%, marketing 39.4%, operating margin -67.6% 2019FY 2020: revenue $59M, +28% on a year earlier, gross margin 59.5%, marketing 35.4%, operating margin -33.5% FY 2021: revenue $67M, +13.8% on a year earlier, gross margin 61.5%, marketing 42%, operating margin -40.1% 2021FY 2022: revenue $72M, +6.8% on a year earlier, gross margin 59.4%, marketing 39.3%, operating margin -25.9% FY 2023: revenue $84M, +16% on a year earlier, gross margin 60.8%, marketing 31.6%, operating margin -6.7% 2023FY 2024: revenue $100M, +19.2% on a year earlier, gross margin 61.8%, marketing 29.6%, operating margin +7.8% FY 2025: revenue $129M, +29.9% on a year earlier, gross margin 64.3%, marketing 27.4%, operating margin +12.6% 2025
RevenueGross margin (0–100% scale)Marketing (0–100% scale)
Niagen Bioscience by fiscal year
Fiscal yearRevenueGrowthGross marginMarketingOp. marginNet marginSource
2025ends 2025-12-31 $129M+29.9%64.3% 27.4%+12.6%+13.4% 10-K filed 2026-03-04
2024ends 2024-12-31 $100M+19.2%61.8% 29.6%+7.8%+8.6% 10-K filed 2026-03-04
2023ends 2023-12-31 $84M+16%60.8% 31.6%-6.7%-5.9% 10-K filed 2025-03-04
2022ends 2022-12-31 $72M+6.8%59.4% 39.3%-25.9%-23% 10-K filed 2024-03-06
2021ends 2021-12-31 $67M+13.8%61.5% 42%-40.1%-40.2% 10-K filed 2023-03-08
2020ends 2020-12-31 $59M+28%59.5% 35.4%-33.5%-33.6% 10-K filed 2022-03-14
2019ends 2019-12-31 $46M+46.7%55.7% 39.4%-67.6%-69.4% 10-K filed 2021-03-12
2018ends 2018-12-31 $32M+48.8%50.9% 52.4%-105.1%-105.6% 10-K filed 2020-03-10
2017ends 2017-12-30 $21M-2.1%49.4% 21%-77.2%-53.7% 10-K filed 2018-03-15
2016ends 2016-12-31 $22M+21.1%48% 7.2%-13.4%-13.5% 10-K filed 2018-03-15
2015ends 2016-01-02 $18M+16.8%42.1% 8.4%-11.6%-15.5% 10-K filed 2018-03-15
2014ends 2015-01-03 $15M+50.7%34.8% 14%-34.2%-35.2% 10-K filed 2017-03-16
2013ends 2013-12-28 $10M-12.5%30.8% 23.2%-43.2%-43.5% 10-K filed 2016-03-17
2012ends 2012-12-29 $12M+43.1%19.6% 47.5%-100.2%-100.4% 10-K filed 2014-03-27
2011ends 2011-12-31 $8.1M+7.2%30.5% 31.3%-96.9%-97.3% 10-K filed 2013-03-29
2010ends 2011-01-01 $7.6M–38.9% 14.3%-26.7%-27.1% 10-K filed 2012-03-15

Revenue and margins by quarter

The last 16 calendar quarters. Most companies only report Q4 inside their annual report, so Q4 is the full year minus the first three quarters.

Q4 2022: revenue $21M, +18.2% on a year earlier, gross margin 57.2%, marketing 29.5%, operating margin -6.9% Q1 2023: revenue $23M, +30.7% on a year earlier, gross margin 59.9%, marketing 34.9%, operating margin -8.7% Q1 2023Q2 2023: revenue $20M, +21.5% on a year earlier, gross margin 60.8%, marketing 29.6%, operating margin -11.4% Q3 2023: revenue $19M, +14.3% on a year earlier, gross margin 61.4%, marketing 31%, operating margin -5.9% Q3 2023Q4 2023: revenue $21M, +1% on a year earlier, gross margin 61%, marketing 30.8%, operating margin -0.8% Q1 2024: revenue $22M, -1.8% on a year earlier, gross margin 60.7%, marketing 30.4%, operating margin -3.3% Q1 2024Q2 2024: revenue $23M, +11.9% on a year earlier, gross margin 60.2%, marketing 30.6%, operating margin -1.1% Q3 2024: revenue $26M, +31.2% on a year earlier, gross margin 63.5%, marketing 27.5%, operating margin +6.3% Q3 2024Q4 2024: revenue $29M, +37.4% on a year earlier, gross margin 62.5%, marketing 29.9%, operating margin +24.4% Q1 2025: revenue $30M, +37.6% on a year earlier, gross margin 63.4%, marketing 26.6%, operating margin +15.7% Q1 2025Q2 2025: revenue $31M, +36.8% on a year earlier, gross margin 65%, marketing 26.4%, operating margin +10.2% Q3 2025: revenue $34M, +32.9% on a year earlier, gross margin 64.5%, marketing 25.8%, operating margin +12.5% Q3 2025Q4 2025: revenue $34M, +16.2% on a year earlier, gross margin 64.1%, marketing 30.8%, operating margin +12.1% Q1 2026: revenue $31M, +3.3% on a year earlier, gross margin 63.5%, marketing 30.7%, operating margin +5% Q1 2026Q2 2026: revenue $30M, -4.3% on a year earlier, gross margin 64.8%, marketing 34%, operating margin +2.4% Q3 2026: revenue $27M, -20% on a year earlier, gross margin 62.9%, marketing 32%, operating margin -5.8% Q3 2026
RevenueGross margin (0–100% scale)Marketing (0–100% scale)
All 65 quarters
Niagen Bioscience by quarter
QuarterRevenuevs year earlierGross marginMarketingOp. marginSource
Q3 2026 $27M-20%62.9% 32%-5.8% 10-Q filed 2026-11-04
Q2 2026 $30M-4.3%64.8% 34%+2.4% 10-Q filed 2026-08-04
Q1 2026 $31M+3.3%63.5% 30.7%+5% 10-Q filed 2026-05-06
Q4 2025full year minus Q1–Q3 $34M+16.2%64.1% 30.8%+12.1% 10-K filed 2026-03-04
Q3 2025 $34M+32.9%64.5% 25.8%+12.5% 10-Q filed 2026-11-04
Q2 2025 $31M+36.8%65% 26.4%+10.2% 10-Q filed 2026-08-04
Q1 2025 $30M+37.6%63.4% 26.6%+15.7% 10-Q filed 2026-05-06
Q4 2024full year minus Q1–Q3 $29M+37.4%62.5% 29.9%+24.4% 10-K filed 2026-03-04
Q3 2024 $26M+31.2%63.5% 27.5%+6.3% 10-Q filed 2025-11-04
Q2 2024 $23M+11.9%60.2% 30.6%-1.1% 10-Q filed 2025-08-06
Q1 2024 $22M-1.8%60.7% 30.4%-3.3% 10-Q filed 2025-05-07
Q4 2023full year minus Q1–Q3 $21M+1%61% 30.8%-0.8% 10-K filed 2025-03-04
Q3 2023 $19M+14.3%61.4% 31%-5.9% 10-Q filed 2024-10-31
Q2 2023 $20M+21.5%60.8% 29.6%-11.4% 10-Q filed 2024-08-07
Q1 2023 $23M+30.7%59.9% 34.9%-8.7% 10-Q filed 2024-05-08
Q4 2022full year minus Q1–Q3 $21M+18.2%57.2% 29.5%-6.9% 10-K filed 2024-03-06
Q3 2022 $17M-1.4%59.8% 34.4%-18% 10-Q filed 2023-11-08
Q2 2022 $17M-5.5%60% 47.9%-38.2% 10-Q filed 2023-08-09
Q1 2022 $17M+17.5%61% 47.7%-44.8% 10-Q filed 2023-05-10
Q4 2021full year minus Q1–Q3 $18M+15%61.2% 48.7%-29.9% 10-K filed 2023-03-08
Q3 2021 $17M+22.1%61.1% 41.7%-51.1% 10-Q filed 2022-11-02
Q2 2021 $18M+15.8%61.1% 35.2%-31.4% 10-Q filed 2022-08-10
Q1 2021 $15M+2.4%62.9% 42.6%-50.1% 10-Q filed 2022-05-12
Q4 2020full year minus Q1–Q3 $15M+18%61% 40.9%-39.4% 10-K filed 2022-03-14
Q3 2020 $14M+17.6%59.6% 36.8%-29.6% 10-Q filed 2021-11-03
Q2 2020 $15M+37.7%59.4% 32.4%-24.1% 10-Q filed 2021-08-03
Q1 2020 $14M+42.8%57.9% 31%-41.1% 10-Q filed 2021-05-06
Q4 2019full year minus Q1–Q3 $13M+44.4%57% 39%-67.7% 10-K filed 2021-03-12
Q3 2019 $12M+48.4%56% 38.4%-57.1% 10-Q filed 2020-11-04
Q2 2019 $11M+42.3%56.3% 38.8%-64.7% 10-Q filed 2020-08-06
Q1 2019 $10M+53%52.8% 41.5%-83.3% 10-Q filed 2020-05-18
Q4 2018full year minus Q1–Q3 $9.1M+20.4%52% 51.4%-90.9% 10-K filed 2020-03-10
Q3 2018 $8.1M+33.4%53.7% 59.6%-105.9% 10-Q filed 2019-11-12
Q2 2018 $7.8M+85%49.3% 48.4%-101.7% 10-Q filed 2019-08-07
Q1 2018 $6.6M+95%47.8% 49.8%-127.9% 10-Q filed 2019-05-09
Q4 2017 $7.5M+69.1%50.9% –-116.6% 10-K filed 2018-03-15
Q3 2017 $6.1M+54.5%47.9% 18.1%-52.2% 10-K filed 2018-03-15
Q2 2017 $4.2M-43.2%50% 13%-62.8% 10-K filed 2018-03-15
Q1 2017 $3.4M-42.4%48% 12%-52.6% 10-Q filed 2018-05-10
Q4 2016 $4.5M+2%45.1% –-48.8% 10-K filed 2018-03-15
Q3 2016 $3.9M-37.4%47.3% 7.3%-23.5% 10-K filed 2018-03-15
Q2 2016 $7.4M+21.7%49.5% 9.4%+2.1% 10-K filed 2018-03-15
Q1 2016 $5.9M+11.2%48.6% 9.3%+0.5% 10-K filed 2018-03-15
Q4 2015 $4.4M+2.9%36.7% –-28.4% 10-K filed 2017-03-16
Q3 2015 $6.3M+51.9%39.5% 8.8%+2.8% 10-K filed 2017-03-16
Q2 2015 $6.1M+58.2%40.5% 10.5%-3% 10-K filed 2017-03-16
Q1 2015 $5.3M+71.1%36.6% 11.1%-17.2% 10-Q filed 2016-05-12
Q4 2014 $4.2M+76.7%33.4% –-26% 10-K filed 2017-03-16
Q3 2014 $4.1M+52.3%36.8% 12.5%-15.6% 10-K filed 2017-03-16
Q2 2014 $3.9M+42.5%36.3% 14.8%-42.6% 10-K filed 2017-03-16
Q1 2014 $3.1M+31.7%32% 15.1%-59.8% 10-K filed 2017-03-16
Q4 2013 $2.4M-31.8%31.2% –-29.8% 10-K filed 2016-03-17
Q3 2013 $2.7M-25.2%27.6% 18.6%-45.7% 10-K filed 2016-03-17
Q2 2013 $2.7M+1.4%35.5% 23.3%-37.4% 10-K filed 2016-03-17
Q1 2013 $2.3M+30.8%28.8% 31.2%-60.7% 10-K filed 2016-03-17
Q4 2012full year minus Q1–Q3 $3.5M+94.9%24.4% 28.1%-48% 10-K filed 2014-03-27
Q3 2012 $3.6M+98.7%34.5% 22.1%-42.2% 10-Q filed 2013-11-21
Q2 2012 $2.7M+37.8%28.6% 70%-149.3% 10-Q/A filed 2013-12-05
Q1 2012 $1.8M-29.7%-33.8% 104.1%-247.9% 10-Q/A filed 2013-12-05
Q4 2011full year minus Q1–Q3 $1.8M–22.3% 48.5%-137.4% 10-K filed 2013-03-29
Q3 2011 $1.8M+17%25.5% 35.6%-131.2% 10-Q filed 2011-11-10
Q2 2011 $1.9M-4.7%30% 29.2%-94.7% 10-Q filed 2011-08-11
Q1 2011 $2.5M–40.2% 17.5%-45.2% 10-Q filed 2012-05-10
Q3 2010 $1.6M–32.2% 15.1%-55.9% 10-Q filed 2011-11-10
Q2 2010 $2M–38.1% 11.2%-14.4% 10-Q filed 2011-08-11

Sources

Every figure is from Niagen Bioscience's SEC filings (XBRL data in its 10-K and 10-Q reports): all filings on SEC EDGAR. Each row above links to the filing it came from.

Marketing is whatever the company reports as marketing, advertising or selling and marketing, so definitions differ between companies. Rankings compare each brand's latest 12 months (US) or latest fiscal year (Europe).

All D2C benchmarks

From the team behind this directory

You've seen how Niagen Bioscience does it. Now see how yours compares.

Bratrax connects to your Shopify store and ad accounts and shows you the numbers that decide whether you're making money: profit after ad spend and product costs, which channels bring customers who come back, and where your next dollar should go.

$1 first month · then $99/month flat · no contract

  • Revenue, ad spend, MER and profit for the whole store on one screen
  • Every order traced back to the campaign that brought it
  • New vs. returning customers, cohorts and lifetime value
  • Email campaigns and flows, with the revenue they drove
  • Ask questions in plain English with your own Claude